We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

AKRBP:EURONEXT OSLOAker BP ASA Analysis

Data as of 2026-03-14 - not real-time

NOK 318.80

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Technical outlook: Aker BP is trading at 318.8 NOK, comfortably above its 20‑day (294), 50‑day (280) and 200‑day (260) simple moving averages, confirming a strong bullish price trend. The 14‑day RSI sits at 70, indicating the stock is in overbought territory, while the MACD line (10.97) remains above its signal (8.96), supporting continued upside momentum. Volume is increasing and beta is very low (≈0.2), suggesting limited market‑wide volatility, though 30‑day price volatility is high at roughly 33%.
Fundamental outlook: The equity appears dramatically overvalued, with a trailing P/E of 156 versus an industry average of 22, and a DCF‑derived fair value of only 93.5 NOK – a downside of about 15% from current levels. Nevertheless, the company delivers a generous 7.98% dividend yield with a modest payout ratio (~12%), and recent news highlights the start of production from the Solveig Phase 2 development and solid Q4 2025 operational performance. However, free cash flow is negative and capex has been raised to up to $6.7 bn, adding pressure on cash generation. Overall, the stock’s price reflects strong market optimism but lacks supporting earnings growth.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • RSI in overbought zone
  • Current price far above DCF fair value
  • Recent ex‑dividend date may trigger short‑term sell pressure

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong dividend yield with low payout ratio
  • Increasing capex could pressure cash flow
  • Technical bullish bias but valuation concerns

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Low beta and stable Norwegian operating environment
  • Sustainable dividend policy despite earnings volatility
  • Potential for valuation correction as earnings catch up

Key Metrics & Analysis

Financial Health

Revenue Growth-16.50%
Profit Margin1.21%
P/E Ratio156.3
ROE1.11%
ROA9.47%
Debt/Equity86.74
P/B Ratio1.8
Op. Cash FlowNOK7.0B
Free Cash FlowNOK-1694937472
Industry P/E22.2

Technical Analysis

TrendBullish
RSI70.0
SupportNOK 265.50
ResistanceNOK 322.80
MA 20NOK 294.06
MA 50NOK 280.10
MA 200NOK 260.38
MACDBullish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair ValueNOK 93.49
Target PriceNOK 271.28
Upside/Downside-14.91%
GradeOvervalued
TypeValue
Dividend Yield7.98%

Risk Assessment

Beta0.22
Volatility33.07%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.